Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology virtual congress

Phase 2 expansion cohort data supports ongoing Phase 3 trial Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that it will present additional data on its lead partnered asset, monalizumab, at the ESMO Immuno-oncology Virtual Congress being held from Dec. 9-12, 2020. Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells. The presentation will include updated results from a Phase 2 study investigating the combination of monalizumab and cetuximab in patients with recurrent or metastatic head and neck squamous cell cancer (R/M SCCHN) who have been previously treated with a platinum-based chemotherapy and PD-(L)1 inhibitor. The e-poster presentation (#81P, abstract #235) entitled, “Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Updated results from a phase 2 trial” will be available on Dec. 9th. As recently announced , AstraZeneca dosed the first patient in its Phase 3 clinical trial, INTERLINK-1, evaluating monalizumab in combination with cetuximab in R/M SCCHN patients who have been previously treated with a platinum-based chemotherapy and PD-(L)1 inhibitors. Subscribe to our newsletter Contact us 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30

The release as fetched from its publisher. innate-pharma.com ↗